Horan Christopher sold $71K of ARTV

Horan Christopher (Chief Tech Operations Officer) sold 10,340 shares of Artiva Biotherapeutics, Inc. (ARTV) at $6.84 on 2026-10-05.

Original reporting
SEC EDGAR · Horan Christopher
Published Oct 6, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock, but it provides transparency for investors.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical trial milestones for Artiva that could outweigh the small sell‑off.

Relevance 3/10Novelty 3/10Timing: filed today (Oct 6)

Background

Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

Chief Tech Operations Officer sold 10,340 shares for $70,696, reducing his stake to 312,744 shares.

Expected impact

likely slight downward pressure as market prices in the insider sale.

Evidence & confidence

The transaction is small relative to market cap and does not materially affect supply‑demand dynamics.

Market effects

No broader sector impact; biotech sector unchanged.

U.S. market only; no regional effect.

Minimal global relevance.

Counterpoint

If the insider is privy to upcoming positive news, the sale could be a temporary liquidity move, not a bearish signal.

Key entities

  • Artiva Biotherapeutics, Inc.

    Biotech firm developing gene‑therapy products.

  • Horan Christopher

    Chief Tech Operations Officer at Artiva.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.